Why the study?
Does heparin prophylaxis and therapy reduce mortality from venous thromboembolism in high-risk patients and those with established thrombosis?
Does heparin prophylaxis and therapy reduce mortality from venous thromboembolism in high-risk patients and those with established thrombosis?
Heparin is highlighted as an effective and safe anticoagulant for both the prophylaxis of VTE in high-risk surgical patients and the management of established thrombosis.
Lowering the mortality from venous thromboembolism depends on effective prophylaxis including use of anticoagulants in high-risk patients, and on adequate anticoagulant therapy for established thrombosis. Heparin in low doses given subcutaneously seems effective and safe as prophylaxis in high-risk surgical patients. Heparin is also the drug of choice for managing established venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Hirsh et al. (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: